

Ganesh Prasanna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/679401/publications.pdf>

Version: 2024-02-01

17
papers

411
citations

759233

12
h-index

996975

15
g-index

17
all docs

17
docs citations

17
times ranked

451
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Understanding metabolism related differences in ocular efficacy of MGV354. <i>Xenobiotica</i> , 2021, 51, 5-14. | 1.1 | 2 |
| 2 | Application of Cell Impedance as a Screening Tool to Discover Modulators of Intraocular Pressure. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2020, 36, 269-281. | 1.4 | 2 |
| 3 | Using Healthcare Databases to Refine Understanding of Exploratory Associations Between Drugs and Progression of Open-Angle Glaucoma. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 874-883. | 4.7 | 13 |
| 4 | Glaucoma - Next Generation Therapeutics: Impossible to Possible. <i>Pharmaceutical Research</i> , 2019, 36, 25. | 3.5 | 32 |
| 5 | The Discovery of (S)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazol-4-yl)ethanone, a Soluble Guanylate Cyclase Activator Specifically Designed for Topical Ocular Delivery as a Therapy for Glaucoma. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2552-2570. | 6.4 | 11 |
| 6 | Binding of a glaucoma-associated myocilin variant to the β -crystallin chaperone impedes protein clearance in trabecular meshwork cells. <i>Journal of Biological Chemistry</i> , 2018, 293, 20137-20156. | 3.4 | 15 |
| 7 | A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing. , 2018, 59, 1704. | | 19 |
| 8 | A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma. <i>American Journal of Ophthalmology</i> , 2018, 192, 113-123. | 3.3 | 15 |
| 9 | A murine glaucoma model induced by rapid in vivo photopolymerization of hyaluronic acid glycidyl methacrylate. <i>PLoS ONE</i> , 2018, 13, e0196529. | 2.5 | 19 |
| 10 | A Compact Whole-Eye Perfusion System to Evaluate Pharmacologic Responses of Outflow Facility. , 2017, 58, 2991. | | 13 |
| 11 | Effects of Rho Kinase Inhibitors on Intraocular Pressure and Aqueous Humor Dynamics in Nonhuman Primates and Rabbits. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2016, 32, 355-364. | 1.4 | 20 |
| 12 | Pharmacology of novel intraocular pressure-lowering targets that enhance conventional outflow facility: Pitfalls, promises and what lies ahead?. <i>European Journal of Pharmacology</i> , 2016, 787, 47-56. | 3.5 | 16 |
| 13 | Effect of PF-04217329 a prodrug of a selective prostaglandin EP2 agonist on intraocular pressure in preclinical models of glaucoma. <i>Experimental Eye Research</i> , 2011, 93, 256-264. | 2.6 | 51 |
| 14 | Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating Prostaglandin F ₂ agonist, in preclinical models. <i>Experimental Eye Research</i> , 2011, 93, 250-255. | 2.6 | 103 |
| 15 | Correlation of <i>In Vitro</i> and <i>In Vivo</i> Kinetics of Nitric Oxide Donors in Ocular Tissues. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2009, 25, 105-112. | 1.4 | 28 |
| 16 | Corneal Neovascularization and Ocular Irritancy Responses in Dogs Following Topical Ocular Administration of an EP4-Prostaglandin E ₂ Agonist. <i>Toxicologic Pathology</i> , 2009, 37, 911-920. | 1.8 | 16 |
| 17 | Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models. <i>Experimental Eye Research</i> , 2009, 89, 608-617. | 2.6 | 36 |